Search Results - "Long-Roche K"

Attitudes towards risk‐reducing salpingectomy: listen to the patients.

Authors: Long Roche, K¹ (AUTHOR) longrock@mskcc.org

Source: BJOG: An International Journal of Obstetrics & Gynaecology. Mar2021, Vol. 128 Issue 4, p727-727. 1p.

Barriers to early detection: Insurance denials for breast MRI screening in women with germline BRCA1/2 mutations.

Authors: Gordhandas, S. Gellman, C. Ingber, S. et al.

Source: Gynecologic Oncology. Feb2025, Vol. 193, p20-23. 4p.

Trends and factors associated with radical cytoreductive surgery in the United States: A case for centralized care.

Authors: Sinno, A.K. Li, X. Thompson, R.E. et al.

Source: Gynecologic Oncology. Jun2017, Vol. 145 Issue 3, p493-499. 7p.

013 The Development and Implementation of a Gynecologic Cancer Survivorship Tool.

Authors: Carter, J. Abu-Rustum, N. Saban, S. et al.

Source: Journal of Sexual Medicine. 2020 Supplement 3, Vol. 17, pS6-S6. 1p.

Impact of adjuvant chemotherapy in patients with FIGO stage I endometrioid ovarian carcinoma in the platinum era: A Surveillance, Epidemiology, and End Results cohort study, 2000-2013.

Authors: Oseledchyk, A. Leitao, M.M. Aghajanian, C. et al.

Source: Gynecologic Oncology. Jun2017 Supplement 1, Vol. 145, p195-196. 2p.

Trocar site hernia formation in patients undergoing robotically assisted and non-robotically assisted laparoscopic staging surgery for endometrial cancer.

Authors: Cybulska, P. Schiavone, M.B. Sawyer, B. et al.

Source: Gynecologic Oncology. Jun2017 Supplement 1, Vol. 145, p193-194. 2p.

Primary debulking surgery for advanced ovarian cancer: The Kaizen approach to continued improvement in surgical outcomes.

Authors: Tseng, J.H. Cowan, R.A. Thompson, E. et al.

Source: Gynecologic Oncology. Jun2017 Supplement 1, Vol. 145, p197-198. 2p.

Incidence of surgical site infection after implementation of a reduction bundle in gynecologic cancer patients undergoing colon surgery at a comprehensive cancer center.

Authors: Schiavone, M.B. Moukarzel, L.A. Leong, K. et al.

Source: Gynecologic Oncology. Jun2017 Supplement 1, Vol. 145, p13-14. 2p.

Diverting ileostomy during primary cytoreductive surgery for ovarian cancer: Associated factors and postoperative outcomes.

Authors: Tseng, J. Suidan, R.S. Zivanovic, O. et al.

Source: Gynecologic Oncology. Jun2016 Supplement 1, Vol. 141, p49-50. 2p.

Utilization of an institutional algorithm for fertility preservation in young women with endometrial cancer.

Authors: Mueller, J.J. Schiavone, M.B. Cadoo, K. et al.

Source: Gynecologic Oncology. Jun2016 Supplement 1, Vol. 141, p122-123. 2p.

Recurrent ovarian cancer: Can second clinical remission surpass the first?

Authors: Cowan, R.A. Eriksson, A.G.Z. Kim, C.H. et al.

Source: Gynecologic Oncology. Jun2016 Supplement 1, Vol. 141, p174-175. 2p.

Feasibility, safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer.

Authors: Cowan, R.A. Tseng, J.H. Murthy, V. et al.

Source: Gynecologic Oncology. Jun2017 Supplement 1, Vol. 145, p192-192. 1p.

A preoperative algorithm for the management of primary ovarian cancer: A process and outcome evaluation.

Authors: Cowan, R.A. Spross, J. Sarasohn, D. et al.

Source: Gynecologic Oncology. Jun2017 Supplement 1, Vol. 145, p65-65. 1p.

Impact of adjuvant chemotherapy in patients with FIGO stage I ovarian clear cell cancer in the platinum era: A Surveillance, Epidemiology, and End Results cohort study, 2000-2013.

Authors: Oseledchyk, A. Leitao, M.M. Aghajanian, C. et al.

Source: Gynecologic Oncology. Jun2017 Supplement 1, Vol. 145, p194-194. 1p.

Comparison of outcomes in optimally-cytoreduced ovarian cancer patients receiving postoperative intraperitoneal chemotherapy vs intravenous dose-dense chemotherapy without bevacizumab.

Authors: Schlappe, B. O'Cearbhaill, R. Zhou, Q. et al.

Source: Gynecologic Oncology. Jun2017 Supplement 1, Vol. 145, p136-136. 1p.

Surgery at a high-volume center reduces the impact of income on survival for women with advanced ovarian cancer.

Authors: Cowan, R.A. Tseng, J.H. Ali, N. et al.

Source: Gynecologic Oncology. Jun2017 Supplement 1, Vol. 145, p149-149. 1p.

Interval cytoreductive surgical outcome following administration of standard versus dose-dense neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer.

Authors: Mueller, J.J. Kelly, A. Zhou, Q. et al.

Source: Gynecologic Oncology. Jun2016 Supplement 1, Vol. 141, p160-160. 1p.

Mismatch repair abnormalities are associated with aggressive tumor pathology in young women with endometrial cancer.

Authors: Schiavone, M.B. Mueller, J.J. Cadoo, K. et al.

Source: Gynecologic Oncology. Jun2016 Supplement 1, Vol. 141, p125-125. 1p.

Intraperitoneal chemotherapy outcomes following interval cytoreductive surgery for advanced-stage ovarian cancer at a comprehensive cancer center.

Authors: Mueller, J.J. Kelly, A. Zhou, Q. et al.

Source: Gynecologic Oncology. Jun2016 Supplement 1, Vol. 141, p29-29. 1p.

The optimal primary management of bulky stage IIIC ovarian, fallopian tube, and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?

Authors: Sioulas, V. Schiavone, M.B. Zivanovic, O. et al.

Source: Gynecologic Oncology. Jun2016 Supplement 1, Vol. 141, p12-12. 1p.